April 17, 2025
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that it has entered into a conditional exclusive license and distribution agreement (the “Agreement”) for the commercial distribution of its LungLB® test (the “LungLB® test”) in the US with Circulogene Theranostics, Inc. a US liquid biopsy diagnostics company (“Circulogene” or the […]
• Read MoreFebruary 4, 2025
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, provides the following update. As set out in the Operational Update on 19 November 2024, the Company had been actively engaged in discussions with several potential strategic partners. These discussions were aimed at identifying a partner that not only shares the Company’s […]
• Read MoreNovember 19, 2024
Strong progress towards commercialisation of LungLB® LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, provides an update on its operational progress made since the release of its interim results announcement. The Company has continued to execute on the commercial proof of concept of LungLB® and to explore opportunities for a suitable […]
• Read MoreNovember 18, 2024
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block listing pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies: For further information please contact: LungLife AI, Inc. www.lunglifeai.com Paul Pagano, CEO via investors@lunglifeai.com Click here to download […]
• Read MoreNovember 18, 2024
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces the resignation of James McCullough, as a non-executive director of the company, with effect from 24 October 2024. James McCullough has taken the decision to step down from the Board to focus on his Executive role at Renalytix plc. Following this […]
• Read MoreOctober 23, 2024
Further to the Company’s announcement on 04 October 2024, LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, confirms that it has now completed the cancellation and re-issue of certain options as detailed in that announcement. As two of the affected option holders are persons discharging managerial responsibilities, dealings disclosures for […]
• Read MoreOctober 4, 2024
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that the Remuneration Committee has decided to make amendments to the options issued to the Executive Directors at IPO in July 2021, and to those options issued to all current employees in 2021 or upon their appointment. Background and Rationale Under […]
• Read MoreOctober 2, 2024
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces the acceptance for publication of data confirming analytical performance of the Company's blood-based LungLB® test in the journal BMC Pulmonary Medicine. Springer Nature's BMC Pulmonary Medicine is a globally recognised peer-reviewed medical journal with articles covering all aspects of the prevention, diagnosis and management of pulmonary and associated disorders. The […]
• Read MoreSeptember 4, 2024
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, is pleased to announce that our two abstract submissions to the Association for Molecular Pathology1 (AMP) have beenaccepted for both presentation at their flagship 2024 Annual Meeting & Expo in Vancouver, BC, Canada from November 19-23rd, and also for publication in the […]
• Read MoreAugust 22, 2024
LungLife AI, Inc. (the “Company” or “LungLife”) Half-year Report LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, announces its unaudited half-year report for the six months ended 30 June 2024. Strong progress with our LungLB® product Continued operational delivery : Financial Highlights: Commenting Paul Pagano, Chief Executive […]
• Read More
LungLife AI licensure/accreditation information posted here.